Nadofaragene Firadenovec

Phase 3Gene therapy

Nadofaragene Firadenovec is one of 18 small molecule programs targeting Non Muscle Invasive Bladder Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non Muscle Invasive Bladder CancerRecruiting

Non-Muscle Invasive Bladder Cancer With Carcinoma in SituRecruiting

Low-Grade Upper Tract Urothelial CarcinomaRecruiting

Non Muscle Invasive Bladder CancerPhase 3

Recruiting

Non-Muscle Invasive Bladder Cancer With Carcinoma in SituPhase 3

Recruiting

Low-Grade Upper Tract Urothelial CarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

17 competitors in Non Muscle Invasive Bladder Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

3 2

Taxotere

AAvyxa

Phase 3

3 3

Bacillus Calmette-Guerin

AstraZeneca

Phase 3

2 4

Disitamab Vedotin

Pfizer

Phase 2

1 5

Cretostimogene Grenadenorepvec

CCG Oncology, Inc.

Phase 3

3 6

Nadofaragene Firadenovec

Ferring

Phase 3

2 7

Trodelvy

Gilead

Preclinical

1 8

Gemcitabin

GGerman Cancer Research Center

Phase 2

1 9

TARA-002

PProtara Therapeutics

Phase 2

1 10

Theracys® BCG

FFudan University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Muscle Invasive Bladder Urothelial Carcinoma

NCT07332351

Q2 2028

Phase 3Recruiting

Non Muscle Invasive Bladder Cancer

NCT06929286

Q4 2029

PreclinicalRecruiting

Low-Grade Upper Tract Urothelial Carcinoma

NCT06668493

Q4 2030

Phase 3Recruiting

Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT06545955

Clinical

Trials by Indication[1]

Non Muscle Invasive Bladder Cancer2 trials

A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Recruiting· Ferring logo

Ferring·Phase 3·NCT06510374·454 enrolled

COMparative Prospective Assessment Through Clinically Integrated Randomized Trials Evaluating Intravesical Treatments: The COMPARE IT Trial

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT06929286·125 enrolled

Complete Response1 trial

A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

Withdrawn· Ferring logo

Ferring·Phase 4·NCT06390111

Muscle Invasive Bladder Urothelial Carcinoma1 trial

Intravesical Nadofaragene Firadenovec With Neoadjuvant Chemotherapy and Durvalumab in Patients With Muscle Invasive Bladder Cancer (TRIFECTA)

Not yet recruiting·UUniversity of Washington·Phase 2·NCT07332351·33 enrolled

Low-grade Upper Tract Urothelial Carcinoma1 trial

A Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects With Low-grade Upper Tract Urothelial Carcinoma (LG-UTUC)

Recruiting· Ferring logo

Ferring·Preclinical·NCT06668493·20 enrolled

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ1 trial

A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting· Ferring logo

Ferring·Phase 3·NCT06545955·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Nadofaragene Firadenovec. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nadofaragene Firadenovec compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nadofaragene Firadenovec. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ferring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 3[1]
Company: Ferring

Nadofaragene Firadenovec

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Q4 2029

Q4 2030

Trials by Indication[1]

Non Muscle Invasive Bladder Cancer2 trials

Complete Response1 trial

Muscle Invasive Bladder Urothelial Carcinoma1 trial

Low-grade Upper Tract Urothelial Carcinoma1 trial

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ1 trial

References

Drug Info

Quick Facts

Related News